Program
Clarithromycin
Also written as “clarithromycin”, “Clarithromycin ER 500 mg tablets” and “Clarithromycin 500mg”.
Its studies are mostly in Mycobacterium avium-intracellulare Infection · Infections · HIV Infections · Bronchiectasis · Crohn Disease, led by 19 companies.
Drug pageClarithromycin: every studyMany companies study it; this page follows only the 39 they lead. All 152 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Abbott | 50 open or running | phase 3since Mar 22, 2008 | Nov 2, 1999 | none ahead |
| Sun Pharmaceutical Industriesits history only | 50 open or running | phase 1since Oct 15, 2008 | Oct 15, 2008 | none ahead |
| Teva Pharmaceutical Industriesits history only | 40 open or running | phase 1since Feb 2, 2009 | Feb 2, 2009 | none ahead |
| Pfizerits history only | 30 open or running | phase 3since Nov 2, 1999 | Nov 2, 1999 | none ahead |
| Viatrisits history only | 30 open or running | phase 1since Mar 31, 2008 | Mar 31, 2008 | none ahead |
| Boehringer Ingelheimits history only | 20 open or running | phase 1since Nov 2, 1999 | Nov 2, 1999 | none ahead |
| Hikma Pharmaceuticalsits history only | 20 open or running | no phasesince Sep 20, 2007 | Sep 20, 2007 | none ahead |
| HK inno.Nits history only | 20 open or running | phase 1since Jan 7, 2014 | Jan 7, 2014 | none ahead |
| Johnson & Johnsonits history only | 20 open or running | phase 1since Jan 15, 2015 | Jan 15, 2015 | none ahead |
| Novartisits history only | 20 open or running | phase 1since Apr 13, 2009 | Apr 13, 2009 | none ahead |
| Antios Therapeuticsits history only | 10 open or running | phase 1since Oct 28, 2021 | Oct 28, 2021 | none ahead |
| Italfarmacoits history only | 10 open or running | phase 1since Apr 26, 2023 | Apr 26, 2023 | none ahead |
| Jiangsu HengRui Medicineits history only | 11 open or running | phase 1since Jul 6, 2026 | Jul 6, 2026 | none ahead |
| Phathom Pharmaceuticalsits history only | 10 open or running | phase 3since Nov 15, 2019 | Nov 15, 2019 | none ahead |
| PTC Therapeuticsits history only | 10 open or running | phase 1since Nov 4, 2014 | Nov 4, 2014 | none ahead |
| RedHill Biopharmaits history only | 10 open or running | phase 3since Dec 26, 2016 | Dec 26, 2016 | none ahead |
| Shandong Luoxin Pharmaceutical Group Stockits history only | 10 open or running | phase 1since Jun 2, 2023 | Jun 2, 2023 | none ahead |
| Sihuan Pharmaceutical Holdings Groupits history only | 10 open or running | phase 1since May 15, 2020 | May 15, 2020 | none ahead |
| Yuhanits history only | 10 open or running | phase 1since Aug 8, 2013 | Aug 8, 2013 | none ahead |
Also a collaborator on its studies: Genpharm ULC.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Abbott only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 2, 1999First studies: 2 no phase studies in HIV InfectionsFirst studyNCT00002336, NCT00002331
- Nov 2, 1999Phase 1 study in Mycobacterium avium-intracellulare InfectionNCT00000971 · 24 enrolled · United States
- Mar 22, 20082 phase 3 studiesNCT00644553, NCT00645086
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Bacterial 70S ribosome inhibitor”ChEMBL 37, by rule
Studies
All 5 Abbott leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT00645086Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB). · United States, Canada, Puerto Rico | 3 | Completed | Apr 2004 | 465 |
| NCT00644553Acute Bacterial Sinusitis (ABS) · United States, Canada, Greece and more | 3 | Completed | Mar 2004 | 437 |
| NCT00002336HIV Infections · United States | – | Completed | Nov 1994 | |
| NCT00002331HIV Infections · United States, Puerto Rico | – | Completed | Mar 1995 | |
| NCT00000971Mycobacterium avium-intracellulare Infection · United States | 1 | Completed | 24 |
How it is read
Names in the registry
- “Clarithromycin”, 23 entries
- “clarithromycin”, 2 entries
- “Clarithromycin ER 500 mg tablets”, 2 entries
- “Clarithromycin 500mg”, 2 entries
- “RSS0343 Tablet; Clarithromycin Tablets”, 1 entry
Conditions, from the studies’ own filings
- Mycobacterium avium-intracellulare Infection, 3 studies
- Infections, 2 studies
- HIV Infections, 2 studies
- Bronchiectasis, 1 study
- Crohn Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.